Knight Therapeutics (GUD) Rating Reiterated by Raymond James

Raymond James reissued their outperform rating on shares of Knight Therapeutics (TSE:GUD) in a research report report published on Wednesday morning. The brokerage currently has a C$10.25 price objective on the stock.

Separately, Bloom Burton reissued an accumulate rating on shares of Knight Therapeutics in a report on Friday, November 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Knight Therapeutics currently has a consensus rating of Buy and a consensus price target of C$10.06.

Shares of Knight Therapeutics stock opened at C$8.16 on Wednesday. Knight Therapeutics has a 12 month low of C$7.38 and a 12 month high of C$8.81.

Knight Therapeutics (TSE:GUD) last announced its earnings results on Thursday, November 8th. The company reported C$0.03 EPS for the quarter, meeting analysts’ consensus estimates of C$0.03. The firm had revenue of C$3.22 million for the quarter, compared to analyst estimates of C$2.26 million. On average, equities research analysts anticipate that Knight Therapeutics will post 0.129999993308824 earnings per share for the current fiscal year.

About Knight Therapeutics

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Further Reading: Hedge Funds

Analyst Recommendations for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit